This preprint is under consideration at Malaria Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Costs and Cost-Effectiveness of Artesunate Against Quinine Treatment Therapy for Severe Malaria in Children Under 14 Years in Zambia.
Wei Xu
Ministry of health Zambia
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Malaria exerts a significant economic burden on health care providers and households. Also, the cost of inpatient care for a case of severe malaria further exerts a heavy financial burden on most countries with already limited recourses. Therefore, it is essential to provide policy makers with relevant economic evidence on economic benefits of health care control, preventive and curative strategies.
Methods
Cost-effectiveness analysis of severe malaria treatment was conducted from a healthcare provider perspective using a decision tree. Standard costing was performed for the identification, measurement and assessment phases, with data from Zambia annual quantification reports for anti-malaria commodities. The data was collected from Health Management information system, and meta-analysis. Average and incremental cost-effectiveness ratio were estimated. The uncertainties were assessed through probabilistic sensitivity analysis.
Results
Severe Malaria in Children has been shown to account for over 45% of the total monthly curative healthcare costs incurred by households compared to the mean per capita monthly income. The cost of treating severe malaria depleted 7.67% of the monthly average household income. In addition, the cost attributed to loss of income in taking care of a sick child is the highest contributor $10.5 of total cost followed by direct medical costs $7.75. According, to the cost effectiveness analysis the of Artesunate with quinine the ICER was $105 per death averted.
Conclusion
The use of Artesunate over Quinine in the treatment of severe malaria in children under 14years is a highly cost-effective strategy for the healthcare provider in Zambia.
Keywords
Cost-effectiveness, Severe malaria, Quinine, Artesunate, household income, Zambia
Figure 1
Figure 2
Figure 3
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Review #1 received
Received 19 Jan, 2021
Reviewer #4 agreed
On 07 Jan, 2021
Reviewer #2 agreed
On 05 Jan, 2021
Reviewer #3 agreed
On 05 Jan, 2021
Reviewers invited
Invitations sent on 05 Jan, 2021
Reviewer #1 agreed
On 05 Jan, 2021
Editor assigned
On 04 Jan, 2021
Submission checks complete
On 04 Jan, 2021
Editor invited
On 04 Jan, 2021
First submitted
On 03 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This preprint is under consideration at Malaria Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Costs and Cost-Effectiveness of Artesunate Against Quinine Treatment Therapy for Severe Malaria in Children Under 14 Years in Zambia.
Wei Xu
Ministry of health Zambia
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Review #1 received
Received 19 Jan, 2021
Reviewer #4 agreed
On 07 Jan, 2021
Reviewer #2 agreed
On 05 Jan, 2021
Reviewer #3 agreed
On 05 Jan, 2021
Reviewers invited
Invitations sent on 05 Jan, 2021
Reviewer #1 agreed
On 05 Jan, 2021
Editor assigned
On 04 Jan, 2021
Submission checks complete
On 04 Jan, 2021
Editor invited
On 04 Jan, 2021
First submitted
On 03 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Malaria exerts a significant economic burden on health care providers and households. Also, the cost of inpatient care for a case of severe malaria further exerts a heavy financial burden on most countries with already limited recourses. Therefore, it is essential to provide policy makers with relevant economic evidence on economic benefits of health care control, preventive and curative strategies.
Methods
Cost-effectiveness analysis of severe malaria treatment was conducted from a healthcare provider perspective using a decision tree. Standard costing was performed for the identification, measurement and assessment phases, with data from Zambia annual quantification reports for anti-malaria commodities. The data was collected from Health Management information system, and meta-analysis. Average and incremental cost-effectiveness ratio were estimated. The uncertainties were assessed through probabilistic sensitivity analysis.
Results
Severe Malaria in Children has been shown to account for over 45% of the total monthly curative healthcare costs incurred by households compared to the mean per capita monthly income. The cost of treating severe malaria depleted 7.67% of the monthly average household income. In addition, the cost attributed to loss of income in taking care of a sick child is the highest contributor $10.5 of total cost followed by direct medical costs $7.75. According, to the cost effectiveness analysis the of Artesunate with quinine the ICER was $105 per death averted.
Conclusion
The use of Artesunate over Quinine in the treatment of severe malaria in children under 14years is a highly cost-effective strategy for the healthcare provider in Zambia.
Figure 1
Figure 2
Figure 3